|
- 积分
- 1132
- 威望
- 1132
- 包包
- 237
|
作者：疑夕
1 m" L9 t9 x- N3 x8 J" c l( _+ i- ?, v
On December 15, 2014, Patrick Soon Shiong, the richest physician in the world, acquired 19.9% of Sorrento Therapeutics (NASDAQ: SRNE)’s equity at $5.80 per share (about 41.7 million). Four days later, Sorrento and Conkwest announced an agreement to co-develop CAR-NK immunotherapy. Sorrento’s stock price reached a high of $11.38 on January 15, 2015.: F. T- H$ R8 k3 E
" }% n2 M, F8 ^/ Y; p/ p* Z
CAR-T cell immunotherapy has been regarded as one of the most compelling breakthroughs in cancer treatment in recent years. Companies working on CAR-T (e.g., JUNO, KITE, BLCM, BLUE, ZIOP) are red hot at present. Sorrento/Conkwest is developing CAR-expressing NK cells rather than T cells to kill cancer cells. How about CAR-TNK compares to CAR-T?
; N! P7 i' P9 L2 p8 _3 N " K+ Y# g- S3 C4 O; d8 a
Here is a comparison published in OncoImmunology[1]. The author, Hans Klingemann, is the inventor of the NK-92 cell line and co-founded ZelleRx in 2002, which was renamed Conkwest in 2010. CAR-NK has many several advantages over CAR-T:7 u) s, D$ Z# L
% n. ^; v" W) S(1) CAR-NK cells don’t produce IL-6 which is associated with the cytokine release syndrome. A series of patient deaths in the trials of CAR-T were linked to unusually high levels of IL-6.
. u% _% L# z% o7 f6 h6 z$ X
* O H( x0 c7 m(2) CAR-NK cells disappear relatively rapidly from the circulation owing to their limited lifespan. There is no concern about persisting CAR-associated side effects. Whereas Juno Therapeutics has to insert EGFRt gene into the CAR-T cells to control them.' V* y& M$ ?5 Z1 t! K
' V# A- T6 k/ O1 [9 o7 S5 y! C$ w
(3) NK cells are known as serial killers which diligently moves from one target to the next one, killing on as many as 7-10 cells.' u7 J4 X' z8 `0 y
+ `! ~6 V* E( f
(4) The transfection efficiency of NK-92 cells is about 50%, even with non-viral methods. Avoiding viral vectors eliminates the risks of oncogene activation and insertional mutagenesis.3 u. s; T/ @1 a
4 @3 O. |& p) M& O2 C9 `
(5) CAR-NK cells can also be produced in large scaleunder GMP conditions. Moerover, it may be used in the setting of allogeneic transplantation.
: e P7 X4 L) X1 T
1 M; K; D+ x3 ~3 g2 ^: ]% H. Y/ hNaturally, only about 10% of circulating lymphocytes are NK cells. The activation of NK cells is determined by the balance of inhibitory and activating receptor stimulation. MHC class I molecules in normal cells inhibit the activation of NK cells.
) `( z P% j! e7 C- a8 a : q0 x& N5 f- r/ H1 E z
Natural NK cells do not express antigen specific receptors. Can CAR-NK cells equipped with an antigen specific receptor kill cancer cells as effectively as CAR-T cells? Hard to say.& l. }5 w* Y" ~0 J: \/ [0 h
, z) Q( F) w E( `! D Q
Preclinical studies in leukemia, lymphoma, and multiple myeloma have been reported. For instance, treatment with anti-CS1 CAR-NK cells prolonged the survival of multiple myeloma mice from 40 days to 50 days[2].
& J7 D2 j9 J8 Y, Z / `" n' d4 O$ s9 G
Sorrento intends to develop anti-CD19, anti-PDL1, anti-PSMA, and anti-CD123 CAR-NK cells. It is expected to initiate Phase I trials in 2016.
* N i1 E' j4 L0 E# l
3 m, U! k K. h. i0 ]9 ]. f" A* x% T& V[1] Oncoimmunology. 2014, 3, e28147. doi: 10.4161/onci.28147.
2 i- J. L. E7 @7 y: E[2] Leukemia. 2014, 28(4), 917-927. % e5 @/ F T$ g
9 u x" @5 I" c8 ~& k* L
Related Articles:( S! p4 o( c. n& j' h+ g
What are the next generation T cell immunotherapies |
-
总评分: 威望 + 2
包包 + 10
查看全部评分
|
发表于 2015-11-11 10:59
